Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5066)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Sep 27, 2022 (publication date) through Nov 9, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Shen K, Singh AD, Modaresi Esfeh J, Wakim-Fleming J. Therapies for non-alcoholic fatty liver disease: A 2022 update. World J Hepatol 2022; 14(9): 1718-1729 [PMID: 36185717 DOI: 10.4254/wjh.v14.i9.1718] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v14/i9/1718.htm |
| Number | Citing Articles |
| 1 |
Fatima Ali Raza, Rafiya Altaf, Talha Bashir, Fatima Asghar, Rabiya Altaf, Sohaib Tousif, Aman Goyal, Aisha Mohammed, Mahnoor Faisal Mohammad, Mahfuza Anan, Sajjad Ali. Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review. Medicine 2024; 103(44): e40364 doi: 10.1097/MD.0000000000040364
|
| 2 |
Femmy Nurul Akbar, Safira Rosiana Choirida, Ahmad Zaqi Muttaqin, Fika Ekayanti, Hoirun Nisa, Hari Hendarto. Telemedicine as an Option for Monitoring Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Patients Facing the COVID-19 Pandemic: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine 2024; 14(3): 281 doi: 10.3390/jpm14030281
|
| 3 |
Sima Jafarirad, Reza Goodarzi, Narges Mohammadtaghvaei, Maryam Dastoorpoor, Pejman Alavinejad. Effectiveness of the pomegranate extract in improving hepatokines and serum biomarkers of non-alcoholic fatty liver disease: A randomized double blind clinical trial. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2023; 17(1): 102693 doi: 10.1016/j.dsx.2022.102693
|
| 4 |
Changzhen Fu, Meng-Lin Xiang, Shaolang Chen, Geng Dong, Zibo Liu, Chong-Bo Chen, Jiajian Liang, Yingjie Cao, Mingzhi Zhang, Qingping Liu. Molecular Drug Simulation and Experimental Validation of the CD36 Receptor Competitively Binding to Long-Chain Fatty Acids by 7-Ketocholesteryl-9-carboxynonanoate. ACS Omega 2023; 8(31): 28277 doi: 10.1021/acsomega.3c02082
|
| 5 |
Yuval Ishay, Joel Neutel, Yotam Kolben, Ram Gelman, Orly Sneh Arbib, Oliver Lopez, Helena Katchman, Rizwana Mohseni, Miriam Kidron, Yaron Ilan. Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial. Gastro Hep Advances 2024; 3(3): 417 doi: 10.1016/j.gastha.2023.11.016
|
| 6 |
雯 郭. Research Progress of Porphyrin Metabolism in Fatty Liver Disease. Advances in Clinical Medicine 2024; 14(07): 321 doi: 10.12677/acm.2024.1472017
|
| 7 |
Yu-long Hu, Qiaoli Ma, Xiaoqiang Dong, Yuanfang Kong, Juntao Cai, Jieming Li, Chunhong Dong. Research progress on the therapeutic effects of polysaccharides on non-alcoholic fatty liver diseases. Frontiers in Nutrition 2023; 10 doi: 10.3389/fnut.2023.1107551
|